How are you approaching patients who receive neoadjuvant chemo immunotherapy for resectable NSCLC who after completion of neoadjuvant treatment are no longer surgical candidates due to factors such as toxicity, decline in PS, or patient preference?

Answer from: Medical Oncologist at Academic Institution

This scenario seems to happen in 17-20% of patients. It’s very important to appropriately stage patients at diagnosis with PET CT, EBUS, etc to ensure accurate staging without which a good discussion regarding resectability is not possible. If a patient does, in spite of our due diligence, end...

Comments

Medical Oncologist at Wentworth Douglass Hospital
If the patient becomes non surgical due to his unr...

Radiation Oncologist at UCLA | VA Greater Los Angeles Healthcare System
That's a good question. Especially since locally a...

Radiation Oncologist at SUNY Upstate Medical University
This is becoming more common, and the answer may c...

Radiation Oncologist at Quillen VA Medical Center
Defining “resectable” is commonly pers...

Please select the option that best describes you:

How are you approaching patients who receive neoadjuvant chemo immunotherapy for resectable NSCLC who after completion of neoadjuvant treatment are no longer surgical candidates due to factors such as toxicity, decline in PS, or patient preference?

Related Questions